1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD. Global prevalence of chronic kidney disease
- a systematic review and meta-analysis. PLoS ONE. 2016;11:
e0158765.
2. Chronic Kidney Disease Prognosis Consortium, Matsushita K,
van der Velde M, Astor BC, Woodward M, Levey AS, de Jong
PE, Coresh J. Gansevoort RT. association of estimated glomerular
filtration rate and albuminuria with all-cause and cardiovascular
mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375:2073–81.
3. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K,
Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ.
Worldwide dialysis outcomes and practice patterns study. healthrelated quality of life among dialysis patients on three continents:
the dialysis outcomes and practice patterns study. Kidney Int.
2003;64:1903–10.
4. Nitta K, Goto S, Masakane I, Hanafusa N, Tanguchi M, Hasegawa
T, Nakai S, Wada A, Hamano T, Hoshino J, Joki N, Abe M,
17. 18. 19. 20. 21. Yamamoto K, Nakamoto H. Annual dialysis data report for 2018,
JSDT Renal data registry: survey methods, facility data, incidence, prevalence, and mortality. Ren Replace Ther. 2020;6:41.
Zhang HW, Lin ZX, Xu C, Leung C, Chan LS. Astragalus (a
traditional Chinese medicine) for treating chronic kidney disease.
Cochrane Database Syst Rev 10: CD008369. (2014)
Zhong Y, Deng Y, Chen Y, Chuang PY, Cijiang HJ. Therapeutic
use of traditional Chinese herbal medications for chronic kidney
diseases. Kidney Int. 2013;84(6):1108–18.
Yoshino T, Horiba Y, Mimura M, Watanabe K. Oral Astragalus
root supplementation for mild to moderate chronic kidney disease:
a self-controlled case-series. Front Pharmacol. 2022;13: 775798.
Verma S, Singh P, Khurana S, Ganguly NK, Kukreti R, Saso L,
Rana DS, Taneja V, Bhargava V. Implications of oxidative stress
in chronic kidney disease: a review on current concepts and therapies. Kidney Res Clin Pract. 2021;40:183–93.
Fujii H, Yonekura Y, Yamashita Y, Kono K, Nakai K, Goto S,
Sugano M, Goto S, Fujieda A, Ito Y, Nishi S. Anti-oxidative
effect of AST-120 on kidney injury after myocardial infarction.
Br J Pharmacol. 2016;173:1302–13.
Yonekura Y, Fujii H, Nakai K, Kono K, Goto S, Shinohara M,
Nishi S. Anti-oxidative effect of the beta-blocker carvedilol on
diabetic nephropathy in non-obese type 2 diabetic rats. Clin Exp
Pharmacol Physiol. 2015;42:972–8.
Nakai K, Fujii H, Kono K, Goto S, Kitazawa R, Kitazawa S,
Hirata M, Shinohara M, Fukagawa M, Nishi S. Vitamin D
activates the Nrf2-Keap1 antioxidant pathway and ameliorates
nephropathy in diabetic rats. Am J Hypertens. 2014;27:586–95.
Fujii H, Kono K, Nakai K, Goto S, Komaba H, Hamada Y,
Shinohara M, Kitazawa R, Kitazawa S, Fukagawa M. Oxidative
and nitrosative stress and progression of diabetic nephropathy
in type 2 diabetes. Am J Nephrol. 2010;31:342–52.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood
Pressure Work Group. KDIGO. Clinical practice guideline for
the management of blood pressure in chronic kidney disease.
Kidney Int. 2021;2021(99):S1–87.
Wu JS, Li JM, Lo HY, Hsiang CY, Ho TY. Anti-hypertensive
and angiotensin-converting enzyme inhibitory effects of Radix
Astragali and its bioactive peptide AM-1. J Ethnopharmacol.
2020;254: 112724.
Li JX, Xue B, Chai Q, Liu ZX, Zhao AP, Chen LB. Antihypertensive effect of total flavonoid fraction of Astragalus complanatus in hypertensive rats. Chin J Physiol. 2005;48(2):101–6.
Wang H, Li J, Yu L, Zhao Y, Ding W. Antifibrotic effect of the
Chinese herbs, Astragalus mongholicus and Angelica sinensis,
in a rat model of chronic puromycin aminonucleoside nephrosis.
Life Sci. 2004;74:1645–58.
Zhang YW, Xie D, Xia B, Zhen RT, Liu IM, Cheng JT. Suppression of transforming growth factor-beta1 gene expression by
Danggui buxue tang, a traditional Chinese herbal preparation,
in retarding the progress of renal damage in streptozotocininduced diabetic rats. Horm Metab Res. 2006;38:82–8.
Hou G, Jiang Y, Zheng Y, Zhao M, Chen Y, Ren Y, Wang C,
Li W. Mechanism of radix astragali and radix salviae miltiorrhizae ameliorates hypertensive renal damage. Biomed Res Int.
2021;2021:5598351.
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–61.
Okuda M, Horikoshi S, Matsumoto M, Tanimoto M, Yasui H,
Tomino Y. Beneficial effect of Astragalus membranaceus on
estimated glomerular filtration rate in patients with progressive
chronic kidney disease. Hong Kong J Nephrol. 2012;14:17–23.
Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa
Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H. Antiangiogenic endostatin peptide ameliorates renal
13
602
22. 23. 24. 25. 26. Clinical and Experimental Nephrology (2023) 27:593–602
alterations in the early stage of a type 1 diabetic nephropathy
model. Diabetes. 2005;54:2891–903.
Yonekura Y, Fujii H, Nakai K, Kono K, Goto S, Shinohara M,
Nishi S. Anti-oxidative effect of the β-blocker carvedilol on
diabetic nephropathy in non-obese type 2 diabetic rats. Clin Exp
Pharmacol Physiol. 2015;42:972–8.
Gao X, Huang L, Grosjean F, Esposito V, Wu J, Fu L, Hu H,
Tan J, He C, Gray S, Jain MK, Zheng F, Mei C. Low-protein
diet supplemented with ketoacids reduces the severity of renal
disease in 5/6 nephrectomized rats: a role for KLF15. Kidney
Int. 2011;79:987–96.
Zhang L, Shergis JL, Yang L, Zhang AL, Guo X, Zhang L,
Zhou S, Zeng L, Mao W, Xue CC. Astragalus membranaceus
(Huang Qi) as adjunctive therapy for diabetic kidney disease:
an updated systematic review and meta-analysis. J Ethnopharmacol. 2019;239: 111921.
Zheng R, Deng Y, Chen Y, Fan J, Zhang M, Zhong Y, Zhu R,
Wang L. Astragaloside IV attenuates complement membranous
attack complex induced podocyte injury through the MAPK
pathway. Phytother Res. 2012;26:892–8.
Shahzad M, Small DM, Morais C, Wojcikowski K, Shabbir A,
Gobe GC. Protection against oxidative stress-induced apoptosis in
13
27. 28. 29. 30. kidney epithelium by Angelica and Astragalus. J Ethnopharmacol.
2016;179:412–9.
Ji C, Luo Y, Zou C, Huang L, Tian R, Lu Z. Effect of astragaloside
IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress. BMC Pharmacol Toxicol. 2018;19:53.
Zheng W, Huang T, Tang QZ, Li S, Qin J, Chen F. Astragalus
polysaccharide reduces blood pressure, renal damage, and dysfunction through the TGF-β1-ILK pathway. Front Pharmacol.
2021;12: 706617.
Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol.
2017;31:17–36.
Guo MF, Dai YJ, Gao JR, Chen PJ. Uncovering the mechanism of astragalus membranaceus in the treatment of diabetic
nephropathy based on network pharmacology. J Diabetes Res.
2020;2020:5947304.
Publisher's Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
...
論文の公開元へ
